Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

recombinant monoclonal antibody

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (3) ADAMTS (1) Akt (2) ALCAM/CD166 (1) Angiotensin-converting Enzyme (ACE) (1) Apoptosis (4) Biochemical Assay Reagents (1) CCR (1) CD19 (1) CD20 (3) CD22 (1) CD47 (1) CD6 (1) Claudin (1) Complement System (2) EGFR (5) ERK (1) Fc Receptor (FcR) (2) Filovirus (2) IGF-1R (3) Integrin (1) Interleukin Related (11) LAG-3 (1) Macrophage migration inhibitory factor (MIF) (1) MMP (1) Neurotensin Receptor (1) Orthopoxvirus (1) P-selectin (1) p38 MAPK (1) PARP (1) PD-1/PD-L1 (2) PI3K (1) RABV (1) Radionuclide-Drug Conjugates (RDCs) (1) RSV (1) SARS-CoV (5) Survivin (1) TGF-beta/Smad (1) TGF-β Receptor (1) Tie (1) TNF Receptor (2) Transmembrane Glycoprotein (3) VAP-1 (1) VEGFR (2)
By Research Areas:	Cancer (43) Cardiovascular Disease (4) Endocrinology (1) Infection (11) Inflammation/Immunology (30) Neurological Disease (2)

By Targets:

ADC Antibody (3)

ADAMTS (1)

Akt (2)

ALCAM/CD166 (1)

Angiotensin-converting Enzyme (ACE) (1)

Apoptosis (4)

Biochemical Assay Reagents (1)

CCR (1)

CD19 (1)

CD20 (3)

CD22 (1)

CD47 (1)

CD6 (1)

Claudin (1)

Complement System (2)

EGFR (5)

ERK (1)

Fc Receptor (FcR) (2)

Filovirus (2)

IGF-1R (3)

Integrin (1)

Interleukin Related (11)

LAG-3 (1)

Macrophage migration inhibitory factor (MIF) (1)

MMP (1)

Neurotensin Receptor (1)

Orthopoxvirus (1)

P-selectin (1)

p38 MAPK (1)

PARP (1)

PD-1/PD-L1 (2)

PI3K (1)

RABV (1)

Radionuclide-Drug Conjugates (RDCs) (1)

RSV (1)

SARS-CoV (5)

Survivin (1)

TGF-beta/Smad (1)

TGF-β Receptor (1)

Tie (1)

TNF Receptor (2)

Transmembrane Glycoprotein (3)

VAP-1 (1)

VEGFR (2)

By Research Areas:

Cancer (43)

Cardiovascular Disease (4)

Endocrinology (1)

Infection (11)

Inflammation/Immunology (30)

Neurological Disease (2)

Inhibitors & Agonists

MCE Kits

Inhibitory Antibodies

Targets Recommended: ADC Antibody Antibody-Drug Conjugates (ADCs) Antibody-Oligonucleotide Conjugates (AOCs) ADC Linker PROTAC-Linker Conjugates for PAC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-108810

Canakinumab Ilaris; ACZ 885	Interleukin Related	Inflammation/Immunology Cancer
Canakinumab (ACZ885) is a recombinant human *anti-IL-1β* monoclonal antibody. Canakinumab shows IC₅₀ values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin .

HY-P99280

Bimekizumab 1 Publications Verification CDP4940; UCB-4940	Interleukin Related	Inflammation/Immunology
Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation .

HY-P99156

Relatlimab 3 Publications Verification BMS-986016	LAG-3	Cancer
Relatlimab (BMS-986016) is a human monoclonal antibody *anti-LAG-3* antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinant LAG-3 protein. Relatlimab blocks LAG-3/MHC II interaction with an IC₅₀ value of 0.67 nM and LAG-3/FGL1 interaction with an IC₅₀ value of 0.019 nM. Relatlimab can be used in research of cancer .

HY-P99275

Patritumab 1 Publications Verification AMG-888; U3-1287	EGFR Akt ERK PARP Survivin	Cancer
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .

HY-P99756

Nirsevimab 2 Publications Verification MEDI8897	RSV	Infection
Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC₅₀ values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections .

HY-P99037

Nipocalimab 3 Publications Verification M281	Fc Receptor (FcR)	Inflammation/Immunology
Nipocalimab (M281) is a fully humanized, recombinant, and non-glycosylated IgG1 monoclonal antibody. Nipocalimab can bind to the IgG-binding site of FcRn with high affinity and inhibit the transplacental transfer of IgG. Nipocalimab can be used in the research of fetal and neonatal hemolytic disease, myasthenia gravis, and various IgG-mediated autoimmune diseases .

HY-P9950

Omalizumab 1 Publications Verification Olizumab; rhuMab-E25; IGE25; RG-3648	Interleukin Related	Inflammation/Immunology Cancer
Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) with a K_D of 0.393 nM. Omalizumab binds to the human FcγRIIb receptors with a K_D of 6.37 uM. Omalizumab has the potential for persistent allergic asthma research . The component ratio of this product is Active ingredient : Excipients = 1:1.3-1:1.5.

HY-P9931

Guselkumab CNTO 1959	Interleukin Related	Inflammation/Immunology
Guselkumab is a recombinant human IgG1 monoclonal antibody against the IL-23p19 subunit. Guselkumab binds to human and cynomolgus monkey IL-23 with K_d values of 3.3 and 1.9 pmol/L, respectively. Guselkumab inhibits production of cytokines lying downstream of the IL-23 signaling pathway and can be used for psoriatic arthritis research .

HY-P9978

Toripalimab JS-001	PD-1/PD-L1	Cancer
Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma .

HY-P99329

Vadastuximab Anti-Human CD33 recombinant antibody	Transmembrane Glycoprotein	Cancer
Vadastuximab (Anti-Human CD33 Recombinant Antibody) is a humanized monoclonal antibody targeting CD33. Vadastuximab can be used to synthesize an ADC compound, Vadastuximab talirine .

HY-P9920A

Ramucirumab (anti-VEGFR) 1 Publications Verification	VEGFR	Cancer
Ramucirumab (anti-VEGFR) is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor .

HY-108831A

Natalizumab (Anti-CD49d) 3 Publications Verification AN100226; BG00002	Integrin	Inflammation/Immunology Cancer
Natalizumab (Anti-CD49d) (AN100226; BG00002) Solution is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d), blocking the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab solution inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 ⁺ T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thereby exerting anti-inflammatory and immunomodulatory activity. Natalizumab (Anti-CD49d) solution is used in the study of relapsing-remitting multiple sclerosis (RRMS) and is also applied in the research of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab (Anti-CD49d) can also prevent lymphocytes from entering the central nervous system, thus preventing acute demyelinating relapses .

HY-P99301

Lokivetmab Anti-Canine IL31 recombinant antibody; CAN34D3-65; PF-06443537	Interleukin Related	Inflammation/Immunology
Lokivetmab (Anti-Canine IL31 Recombinant Antibody) is an anti-canine IL-31 monoclonal antibody. Lokivetmab inhibits IL-31-mediated activation of pruritogenic signals in peripheral sensory neurons and reduces TH2-weighted inflammation. Lokivetmab demonstrates long-term efficacy in controlling pruritus and improving skin lesions in dogs with canine atopic dermatitis (CAD). Lokivetmab can be used for the research of atopic dermatitis (AD) in dogs .

HY-P99294

Ganitumab 1 Publications Verification AMG 479; Human Anti-IGF1R recombinant antibody	IGF-1R	Cancer
Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (K_D=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer .

HY-108852

Basiliximab CHI 621	Interleukin Related	Inflammation/Immunology Cancer
Basiliximab (CHI 621) is a recombinant chimeric murine/human IgG1 monoclonal anti-interleukin-2 receptor antibody. Basiliximab can be used for the research of renal transplantation .

HY-P99351

Andecaliximab Anti-MMP9 Reference antibody (andecaliximab)	MMP	Cancer
Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF) .

HY-P99274

Xentuzumab 1 Publications Verification BI 836845; Anti-Human IGF1 and IGF2 recombinant antibody	IGF-1R	Cancer
Xentuzumab (Anti-Human IGF1 and IGF2 Recombinant Antibody; BI836845) is a recombinant a human monoclonal antibody that targets IGF ligands IGF1 and IGF2. Xentuzumab inhibits both of IGF1 and IGF2 growth-promoting signalling and suppresses AKT activation .

HY-P99332

Visilizumab Anti-Human CD3E recombinant antibody; HuM291	Apoptosis	Inflammation/Immunology Cancer
Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research .

HY-P99328

Tucotuzumab	Interleukin Related	Inflammation/Immunology Cancer
Tucotuzumab (Anti-EPCAM Recombinant Antibody) is an antigen-specific IgG1 monoclonal antibody that targets human epithelial cell adhesion molecule (EpCAM). Tucotuzumab links two IL-2 molecules and is an immunosuppressant and anti-tumor active molecule .

HY-P99262

Imalumab BAX69; Anti-Human MIF recombinant antibody	Macrophage migration inhibitory factor (MIF)	Cancer
Imalumab (BAX69) is a recombinant, human IgG1 monoclonal antibody that targets macrophage inhibitory factor (MIF). Imalumab can be used for the research of ovarian carcinoma, recurrent malignant ascites and cancer .

HY-P99271

Tisotumab Anti-Human F3 recombinant antibody	ADC Antibody	Cancer
Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody and ADC antibody. Tisotumab targets tissue factor (TF). Tisotumab can be used to synthesize antibody-drug conjugates (ADCs) targeting tissue factor (TF), Tisotumab vedotin (HY-152963). Tisotumab can be used for the research of solid tumors .

HY-P99285

Denintuzumab 1 Publications Verification hBU 12	ADC Antibody CD19	Cancer
Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab binds to CD19 on the surface of B cells. Denintuzumab can be used as the antibody moiety (ADC antibody) of antibody-drug conjugates to synthesize ADC, Denintuzumab Mafodotin (SGN-CD19A). Denintuzumab Mafodotin can be used in the research of acute lymphoblastic leukemia .

HY-P9953

Certolizumab pegol 2 Publications Verification Certolizumab; CDP870	TNF Receptor	Inflammation/Immunology Cancer
Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycosylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor-α (TNF-α). Certolizumab pegol can be used for rheumatoid arthritis and Crohn disease research .

HY-P99489

Budigalimab ABBV 181; PR 1648817	PD-1/PD-L1	Inflammation/Immunology Cancer
Budigalimab (ABBV 181; PR 1648817) is a humanized, recombinant IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab has an Fc mutation that reduces the inhibition of Fc receptor interactions and effector factors. Budigalimab can block the binding of PD-1 and PD-L1, which has anti-tumor activity. Budigalimab can be used in the study of solid tumors .

HY-P99496

Cendakimab 1 Publications Verification RPC 4046; ABT 308; CC-93538	Interleukin Related	Inflammation/Immunology
Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC₅₀s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis) .

HY-P990358

Anti-CD7 Antibody	Transmembrane Glycoprotein	Inflammation/Immunology
Anti-CD7 Antibody is a recombinant monoclonal antibody targeting CD7, and it is mainly used as a reference antibody.

HY-P99313

Quilizumab Anti-Human IGHE recombinant antibody	Apoptosis	Inflammation/Immunology
Quilizumab (Anti-Human IGHE Recombinant Antibody) is a humanized IgG1κ monoclonal antibody targeting immunoglobulin epsilon (also konwn as: IGHE, IgE). Quilizumab targets the M1-prime fragment of membrane-expressed IGHE/IgE, leading to IGHE/IgE switching and memory B cell depletion. Quilizumab has potential in asthma research .

HY-P99688

Latozinemab 1 Publications Verification AL001	Neurotensin Receptor	Neurological Disease Cancer
Latozinemab (AL001) is a recombinant human *anti-Sortilin* monoclonal antibody. Latozinemab effectively binds Sortilin with a high affinity and blocks the interaction between progranulin protein (PGRN) and Sortilin receptor. Latozinemab has the potential for progranulin gene (GRN) mutations causative of Frontotemporal dementia (FTD) (FTD-GRN) research .

HY-P99304

Lumretuzumab Anti-Human ERBB3 recombinant antibody	EGFR PI3K Akt p38 MAPK	Cancer
Lumretuzumab (Anti-Human ERBB3 Recombinant Antibody) is a humanized anti-HER3 (ERBB3) monoclonal antibody. Lumretuzumab effectively inhibits the activity of key oncogenic signaling pathways such as PI3K/AKT and MAPK. Lumretuzumab has been optimized through glycosyl engineering to enhance antibody-dependent cell-mediated cytotoxicity (ADCC). Lumretuzumab can be used to study HER3-positive, HER2-low-expressing solid tumors, especially breast cancer .

HY-P99284

Dalotuzumab 1 Publications Verification MK-0646; h7C10	IGF-1R Apoptosis	Cancer
Dalotuzumab (MK-0646) is a recombinant humanized monoclonal antibody (IgG1 type) targeting IGF-1R. Dalotuzumab acts by inhibiting IGF-1- and IGF-2-mediated tumor cell proliferation, IGF-1R autophosphorylation, and Akt phosphorylation. Dalotuzumab also induces apoptosis and cycle arrest. Dalotuzumab in combination with other anticancer agents such as statins can enhance the antitumor activity of Dalotuzumab in vitro and in vivo .

HY-P99326

Tositumomab Anti-Human CD20 recombinant antibody; V10XA53	CD20	Cancer
Tositumomab (Anti-Human CD20 Recombinant Antibody) is a mouse-derived IgG2a monoclonal antibody, targeting to human CD20. Tositumomab can deplete B cells. Tositumomab can be used for the research of cancer, such as lymphoma .

HY-P99335

Vunakizumab Anti-Human IL17A recombinant antibody; SHR-1314	Interleukin Related	Inflammation/Immunology
Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody and an Interleukin-17A (IL-17A) inhibitor. Vunakizumab binds to IL-17A to inhibit downstream cytokines and block inflammatory signaling. Vunakizumab can be used for the research of chronic plaque psoriasis and ankylosing spondylitis .

HY-P99764

Odesivimab 1 Publications Verification REGN-3471	Filovirus	Infection
Odesivimab is a human monoclonal antibody, targeting Ebola virus glycoprotein with a K_D value of 7.74 nM for recombinant histidine-tagged Makona strain Ebola virus glycoprotein ectodomain protein. Odesivimab can be used in research of Ebola virus infection .

HY-P99252

Itolizumab Anti-Human CD6 recombinant antibody	CD6	Infection Inflammation/Immunology
Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant *anti-CD6* monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19 .

HY-P99253

Mogamulizumab 1 Publications Verification KW-0761	CCR	Inflammation/Immunology Cancer
Mogamulizumab (KW-0761) is a recombinant *anti-CCR4* monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL) .

HY-P991550

RFB4	CD22	Cancer
RFB4 is an anti-CD22 monoclonal antibody. RFB4 can be fused with Pseudomonas aeruginosa exotoxin (PE38) via disulfide bonds to construct recombinant immunotoxins, such as RFB4 (dsFv)-PE38. RFB4 is applicable to the research of cancers including lymphoma .

HY-P99347

Etesevimab CB 6; JS016	SARS-CoV Angiotensin-converting Enzyme (ACE)	Infection
Etesevimab (JS016) is a recombinant neutralizing human IgG1 anti-SARS-CoV-2 monoclonal antibody .

HY-P99337

Ansuvimab Ansuvimab-zyk; mAb114	Filovirus	Infection
Ansuvimab (Ansuvimab-zyk) is a recombinant human monoclonal IgG1 antibody that exhibits antiviral activity against Zaire ebolavirus. Ansuvimab binds to the glycoprotein on Zaire ebolavirus to block its entry into host cells .

HY-P99266

Zanolimumab Anti-Human CD4 recombinant antibody	Transmembrane Glycoprotein	Inflammation/Immunology Cancer
Zanolimumab (Anti-Human CD4 Recombinant Antibody) is a fully human monoclonal antibody targets CD4. Zanolimumab effectively inhibits T-cell receptor (TCR) signal transduction. Zanolimumab can be used for the research of heumatoid arthritis, psoriasis, melanoma, cutaneous and peripheral T-cell lymphoma .

HY-P99263

Inclacumab 1 Publications Verification Anti-Human selectin P recombinant antibody	P-selectin	Cardiovascular Disease
Inclacumab (Anti-Human selectin P Recombinant Antibody) is a human monoclonal IgG4 antibody selectively targets P-selectin with a K_d value of 9.9 nM. Inclacumab inhibits P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide bind with P-selectin with an IC₅₀ value of 1.9 μg/mL and strongly inhibits cell adhesion .

HY-P99792

Ormutivimab NM57; rhRIG	RABV	Infection
Ormutivimab (rhRIG) is a recombinant human monoclonal antibody, targeting rabies virus. Ormutivimab neutralizes a variety of rabies virus strains. Ormutivimab exhibits potent potency against rabies post-exposure prophylaxis (PEP) model .

HY-P99178

CTX-471	Interleukin Related	Inflammation/Immunology Cancer
CTX-471 is a fully *human monoclonal* antibody of CD137*. CTX-471 has bind affinity for recombinant* human, cynomolgus macaque CD137 and mouse CD137 with K_d values of 50 nM, 61 nM and 748 nM, respectively. CTX-471 can be used for the research of immunomodulation and cancer .

HY-P99695

Lerdelimumab CAT-152	TGF-beta/Smad	Neurological Disease
Lerdelimumab (CAT-152) is an IgG4 human *anti-TGF-β2* recombinant monoclonal antibody. Lerdelimumab can be used as an anti-scarring agent for glaucoma research .

HY-P991532

AT002 MEMD; EJ212/007-Cl2-5	ALCAM/CD166	Inflammation/Immunology Cancer
AT002 (CBAS-173, EJ212/007-Cl2-5) is a recombinant human IgG1 monoclonal antibody. AT002 targets the cell surface protein activated leukocyte adhesion molecule (ALCAM)/CD166. AT002 can be used in the research of cancer, autoimmune diseases and inflammatory diseases.

HY-P991225

BI-1206	Fc Receptor (FcR) CD20	Inflammation/Immunology Cancer
BI-1206 is a recombinant and antagonistic human monoclonal antibody targeting FcγRIIB (CD32B). BI-1206 can block CD20 internalization induced by Rituximab (HY-P9913) itself or combined with others including Ibrutinib (HY-10997), Venetoclax (HY-15531), and CHOP. BI-1206 can enhance or recover the activity of Rituximab or other anti-CD20 monoclonal antibodies. BI-1206 has cytolytic activity against malignant B cells. BI-1206 can be studied for cancer research such as mantle cell lymphoma (MCL) .

HY-P99952

Ripertamab SCT400	CD20	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Ripertamab (SCT400) is a recombinant human-mouse chimeric anti-CD20 IgG1κ monoclonal antibody. As an immunomodulator, ripertamab reduces the levels of pathogenic autoantibodies, alleviates immune complex deposition, and blocks the antigen-presenting function of cells. Ripertamab depletes CD20-positive cells. Ripertamab can induce infusion-related reactions, pulmonary toxicity, neutropenia and thrombocytopenia. Ripertamab is applicable to research related to non-Hodgkin's lymphoma, primary membranous nephropathy and idiopathic membranous nephropathy .

HY-P99467

Beludavimab BMS 4182137; VIR 7832	SARS-CoV	Infection
Beludavimab (BMS 4182137; VIR 7832) is a monoclonal antibody targeting the spike glycoprotein of SARS-CoV-2. Beludavimab binds to recombinant spike protein receptor-binding domain (S-RBD) with an EC₅₀ value of 14.9 ng/mL and a K_d of 0.21 nM .

HY-P991415

ASKG-712 AM712	VEGFR Tie	Others
ASKG-712 (AM712) is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein. ASKG-712 can be used in Wet age-related macular degeneration and Diabetic macular oedema research .

HY-P99324

Tomuzotuximab Anti-Human EGFR recombinant antibody; CetuxiMab-GEX, GEXMab52201	EGFR Apoptosis	Cancer
Tomuzotuximab (Anti-Human EGFR Recombinant Antibody) is a fully human glycoengineered IgG1 monoclonal antibody against EGFR. Tomuzotuximab has anticancer effects .

HY-P99323

Timolumab BTT 1023; Anti-Human AOC3 recombinant antibody	VAP-1	Inflammation/Immunology
Timolumab (BTT1023 ), a recombinant fully human monoclonal antibody that specifically binds VAP-1. Timolumab (BTT1023 ) could be used in the study of chronic inflammatory diseases .

Cat. No.	Product Name

HY-K0213

Protein A Agarose 5 Publications Verification
MCE Protein A Agarose, a 4% highly cross-linked agarose reagent coupled with recombinant Protein A, effectively purifies mammalian monoclonal and polyclonal antibodies, such as human IgG, IgE, IgM.

HY-K0215

Protein L Agarose 1 Publications Verification
MCE Protein L Agarose, a 4% highly cross-linked agarose reagent coupled with recombinant Protein L, effectively purifies mammalian monoclonal and polyclonal antibodies which have kappa light chain.

HY-K0214

Protein G Agarose Maximum Cited Publications 6 Publications Verification
MCE Protein G Agarose, a 4% highly cross-linked agarose reagent coupled with recombinant Protein G, effectively purifies mammalian monoclonal and polyclonal antibodies, such as human IgG3 and rat IgG2a.

Cat. No.	Product Name	Target	Research Area	Image